ST
Solve Therapeutics develops Antibody Drug Conjugates and Bispecific Therapeutics to target and eliminate cancer cells while minimizing damage to healthy tissue. Their approach addresses the need for more effective and less toxic cancer treatment options in the biopharmaceutical landscape.
Updated 4 months ago
Funding
$176.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Solve Therapeutics develops Antibody Drug Conjugates and Bispecific Therapeutics to target and eliminate cancer cells while minimizing damage to healthy tissue. Their approach addresses the need for more effective and less toxic cancer treatment options in the biopharmaceutical landscape.